FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:1255-1268 April 22, 1999 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Eleven drugs approved by the Food and Drug Administration for the treatment of viral infections (other than those caused by human immunodeficiency virus type 1 [HIV-1] or those complicating such infection) will be reviewed in this article. They are seven nucleoside analogues, two closely related 10-carbon-ring amines, one pyrophosphate analogue, and a recombinant protein produced in bacteria (Figure 1). The characteristics of these antiviral drugs are given in Table 1, management of their adverse effects is outlined in Table 2, and specific recommendations for their use are provided in Table 3.

View larger version (78K): [in this window] [in a new window]   Figure 1. Structures of 11 Antiviral . . . [Full Text of this Article]

 
Approved Drugs

Acyclovir

Valacyclovir

Ganciclovir

Penciclovir

Famciclovir

Foscarnet

Ribavirin

Lamivudine

Amantadine and Rimantadine

Interferon Alfa

Adverse Effects of Antiviral Drugs

Current Issues in Antiviral Therapy

Genital Herpes

Mucocutaneous Herpes

Neonatal Herpes

Herpes Encephalitis

Chickenpox

Herpes Zoster

Respiratory Virus Infections

Hepatitis

Cytomegalovirus Disease

Viral Resistance

Future Directions

Source Information

From the Departments of Laboratory Medicine and Pathology and Pediatrics, University of Minnesota Medical School, Minneapolis.

Address reprint requests to Dr. Balfour at the University of Minnesota Medical School, Box 437 Mayo, 420 Delaware St. S.E., Minneapolis, MN 55455-0392, or at balfo001@tc.umn.edu.

References

This article has been cited by other articles:

• Modrykamien, A. (2010). Review Article: Anemia post--lung transplantation: mechanisms and approach to diagnosis. Chronic Respiratory Disease 7: 29-34 [Abstract]  
• LOPEZ, B. S. G., YAMAMOTO, M., UTSUMI, K., ARATSU, C., SAKAGAMI, H. (2009). A Clinical Pilot Study of Lignin--Ascorbic Acid Combination Treatment of Herpes Simplex Virus. In Vivo 23: 1011-1016 [Abstract] [Full Text]  
• Baillie, G. M. (2006). Prevention of cytomegalovirus disease in solid organ transplant patients: Prophylactic versus preemptive therapy.. Am J Health Syst Pharm 63: S10-S16 [Abstract] [Full Text]  
• Cochrane, A. B. (2006). Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients.. Am J Health Syst Pharm 63: S17-S21 [Abstract] [Full Text]  
• Opstelten, W., van Essen, G. A, Moons, K. G., van Wijck, A. J., Schellevis, F. G, Kalkman, C. J, Verheij, T. J. (2005). Do herpes zoster patients receive antivirals? A Dutch national survey in general practice. Fam Pract 22: 523-528 [Abstract] [Full Text]  
• Baillie, G. M. (2005). Pharmacokinetics of antiviral agents for the treatment of cytomegalovirus infection. Am J Health Syst Pharm 62: S14-S17 [Abstract] [Full Text]  
• Gilbert, C., Boivin, G. (2005). Human Cytomegalovirus Resistance to Antiviral Drugs. Antimicrob. Agents Chemother. 49: 873-883 [Full Text]  
• Lewin, J. J. III, Lapointe, M., Ziai, W. C. (2005). Central Nervous System Infections in the Critically Ill. Journal of Pharmacy Practice 18: 25-41 [Abstract]  
• Anand, B. S., Katragadda, S., Mitra, A. K. (2004). Pharmacokinetics of Novel Dipeptide Ester Prodrugs of Acyclovir after Oral Administration: Intestinal Absorption and Liver Metabolism. J. Pharmacol. Exp. Ther. 311: 659-667 [Abstract] [Full Text]  
• Iyer, R. P., Jin, Y., Roland, A., Morrey, J. D., Mounir, S., Korba, B. (2004). Phosphorothioate Di- and Trinucleotides as a Novel Class of Anti-Hepatitis B Virus Agents. Antimicrob. Agents Chemother. 48: 2199-2205 [Abstract] [Full Text]  
• Aydin, O. F., Senbil, N., Kuyucu, N., Gurer, Y.K. Y. (2003). Combined Treatment With Subcutaneous Interferon-{alpha}, Oral Isoprinosine, and Lamivudine for Subacute Sclerosing Panencephalitis. J Child Neurol 18: 104-108 [Abstract]  
• Chaudhuri, A, Kennedy, P G E (2002). Diagnosis and treatment of viral encephalitis. Postgrad. Med. J. 78: 575-583 [Abstract] [Full Text]  
• Kennedy, P G E, Chaudhuri, A (2002). Herpes simplex encephalitis. J. Neurol. Neurosurg. Psychiatry 73: 237-238 [Full Text]  
• Gavin, P. J., Katz, B. Z. (2002). Intravenous Ribavirin Treatment for Severe Adenovirus Disease in Immunocompromised Children. Pediatrics 110: e9-9 [Abstract] [Full Text]  
• Acosta, E. P., Balfour, H. H. Jr. (2001). Acyclovir for Treatment of Postherpetic Neuralgia: Efficacy and Pharmacokinetics. Antimicrob. Agents Chemother. 45: 2771-2774 [Abstract] [Full Text]  
• Carson, C. F., Ashton, L., Dry, L., Smith, D. W., Riley, T. V. (2001). Melaleuca alternifolia (tea tree) oil gel (6%) for the treatment of recurrent herpes labialis. J Antimicrob Chemother 48: 450-451 [Full Text]  
• Schwartz, J. A., Lium, E. K., Silverstein, S. J. (2001). Herpes Simplex Virus Type 1 Entry Is Inhibited by the Cobalt Chelate Complex CTC-96. J. Virol. 75: 4117-4128 [Abstract] [Full Text]  
• Broo, K., Wei, J., Marshall, D., Brown, F., Smith, T. J., Johnson, J. E., Schneemann, A., Siuzdak, G. (2001). Viral capsid mobility: A dynamic conduit for inactivation. Proc. Natl. Acad. Sci. USA 98: 2274-2277 [Abstract] [Full Text]